Read by QxMD icon Read

Melanoma Research

Peter E Hutchinson, John A Halsall, Silvia Popovici, Eftychios Papadogeorgakis, Joy E Osborne, Ian R Powley, Deepthi Dasari, Gerald Saldanha, James H Pringle
The aims of this study were to investigate, in cutaneous malignant melanoma (MM), the integrity of nuclear vitamin D receptor (VDR) signalling, as implied by VDR subcellular location; to investigate the relationship between VDR and tumour progression and the inhibitory effect on VDR by mitogen-activated protein kinase (MAPK) overactivity. Archived tissue from 34 benign melanocytic naevi, 149 MMs and 44 matched metastases were stained by immunohistochemistry for VDR and a subset of primary MMs were stained for phosphorylated-extracellular signal-regulated kinase as a marker of MAPK activity...
July 12, 2018: Melanoma Research
Laura K Ferris, Pedram Gerami, Maral K Skelsey, Gary Peck, Catherine Hren, Christopher Gorman, Tana Frumento, Daniel M Siegel
About 3 million surgical pigmented skin lesion biopsies are performed each year in the USA alone to diagnose fewer than 200 000 new cases of invasive melanoma and melanoma in situ using the current standard of care that includes visual assessment and histopathology. A recently described noninvasive adhesive patch-based gene expression rule-out test [pigmented lesion assay (PLA)] may be helpful in identifying high-risk pigmented skin lesions to aid with surgical biopsy decisions. The main objective of this utility study was to determine the real-world clinical performance of PLA use and assess how the PLA changes physician behavior in an observational cohort analysis of 381 patients assessed with the PLA...
July 12, 2018: Melanoma Research
Johan Lyth
Conditional survival in patients with localized primary cutaneous malignant melanoma (CMM) is well described. However, conditional recurrence-free survival (RFS) has not been investigated before. The aim of this study was to determine conditional RFS and test for time dependency in prognostic factors in patients with localized stage I-II CMM. This study included 1437 CMM patients registered in one region of Sweden during 1999-2012 followed up through 31 December 2012. To identify first recurrence of CMM disease, data from a care data warehouse, the pathology and radiology department registries were used...
July 9, 2018: Melanoma Research
Marie Lamiaux, Camille Scalbert, Pauline Lepesant, Eve Desmedt, Carole Templier, Véronique Dziwniel, Delphine Staumont-Sallé, Laurent Mortier
Targeted therapy combination (TTC: antiRAF+antiMEK) is known to improve metastatic melanoma survival. Few severe skin toxicities (grade ≥3) are described with first-line TTC (17% for vemurafenib+cobimetinib and none for dabrafenib+trametinib) in a phase III trial. Among our 42 patients treated by TTC between January 2014 and March 2017, 4.8% (2/42) of those treated in the first line presented severe skin rash versus 19% (8/42) of patients treated in the second line after previous immunotherapy. In particular, we observed one case of Stevens-Johnson syndrome and four cases of severe drug reaction with eosinophilia and systemic symptoms syndrome under TTC in patients who had received immunotherapy previously...
July 6, 2018: Melanoma Research
Ivan Gorlov, Irene Orlow, Carol Ringelberg, Eva Hernando, Marc S Ernstoff, Chao Cheng, Stephanie Her, Joel S Parker, Cheryl L Thompson, Meg R Gerstenblith, Marianne Berwick, Christopher Amos
Factors influencing melanoma survival include sex, age, clinical stage, lymph node involvement, as well as Breslow thickness, presence of tumor-infiltrating lymphocytes based on histological analysis of primary melanoma, mitotic rate, and ulceration. Identification of genes whose expression in primary tumors is associated with these key tumor/patient characteristics can shed light on molecular mechanisms of melanoma survival. Here, we show results from a gene expression analysis of formalin-fixed paraffin-embedded primary melanomas with extensive clinical annotation...
July 2, 2018: Melanoma Research
Nieves Gómez-León, Vilma Pacheco-Barcia, Ana I Ballesteros, Javier Fraga, Ramon Colomer, Alfonsa Friera
Malignant melanoma solitary metastases to bone or skeletal muscle occur in 0.8% of patients. The aim of this study was to evaluate features of skeleton and muscle metastases with multimodality imaging and review the oncological outcome. Thirteen patients with melanoma metastases from January 2006 to February 2016 were included. Histologic confirmation was obtained. Imaging studies included computed tomography (CT), MRI, and/or positron emission tomography/CT. Treatment received and BRAF status were recorded...
July 2, 2018: Melanoma Research
Vincas Urbonas, Giedre Smailyte
The use of monoclonal antibodies against programmed cell death protein 1 (anti-PD-1) has markedly transformed the management of melanoma. However, only a minority of patients treated with anti-PD-1 therapy show a response to therapy and some of them develop immune-related adverse events that can be managed with steroids or anticytokine therapy. A recent study published in Nature Communications has reported that treatment with anti-PD-1 in a tumor necrosis factor-deficient environment may lead to higher response rates to immunotherapy by reducing tumor-infiltrating lymphocytes death, accumulating dendritic cells within cancer, and downregulating T-cell immunoglobulin and mucin-domain-containing-3 expression...
June 29, 2018: Melanoma Research
Pooja H Rambhia, Kord Honda, Joshua Arbesman
Immune checkpoint inhibitors targeting the programmed cell death (PD)-1 receptor have dramatically changed the landscape of metastatic melanoma treatment. Nevertheless, these immuno-modulatory agents have associated side effects, including dermatologic manifestations. To this end, we report a patient with metastatic melanoma that was treated with PD-1 inhibitor, and subsequently developed inflammation of existing seborrheic keratosis lesions and new verrucous keratoses, a cutaneous side effect that has not been previously reported to our knowledge...
June 29, 2018: Melanoma Research
Amr Menshawy, Abdelrahman A Eltonob, Sarah A Barkat, Ahmed Ghanem, Mahmoud M Mniesy, Ishak Mohamed, Mohamed Abdel-Maboud, Omar M Mattar, Mohamed Elfil, Eshak I Bahbah, Ahmed Elgebaly
Nivolumab, a completely human programmed death-1 inhibitor antibody, was first approved by the Food and Drug Administration for patients with advanced malignant melanoma resistant to other modalities of treatment. In 2015, it received approval as the first line of treatment for malignant melanoma. We aimed to synthesize evidence from published randomized-controlled trials on the safety and efficacy of nivolumab, either alone or in combination with ipilimumab, in the management of advanced unresectable melanoma...
June 27, 2018: Melanoma Research
Charles J Puza, Andrew S Barbas, Paul J Mosca
A history of melanoma within the preceding 5 years is commonly considered a contraindication to solid organ transplantation. We investigated how a pretransplant history of melanoma impacts patient survival and melanoma recurrence. Institutional Review Board approval was obtained, and Duke's retrospective database was used to identify 4552 patients who underwent a solid organ transplant at Duke University from 1 January 2001 to 31 December 2016. Data with regard to the transplant, melanoma characteristics, rejection episodes, and survival were recorded...
June 25, 2018: Melanoma Research
Esther M Häfliger, Egle Ramelyte, Joanna Mangana, Michael Kunz, Dmitry V Kazakov, Reinhard Dummer, Phil F Cheng
Acral lentiginous melanoma (ALM) is a unique histopathological subtype of melanoma with a poorer prognosis than other cutaneous melanomas. This study aims to evaluate the clinicopathological characteristics, metastatic pattern, prognostic factors, response to systemic therapy, and overall survival (OS) of ALM in a White population. This is a retrospective study of patients who were diagnosed and/or treated for ALM at the Department of Dermatology of the University Hospital Zurich, Switzerland, from January 2005 to December 2015...
May 29, 2018: Melanoma Research
Donatella Iacono, Marika Cinausero, Lorenzo Gerratana, Vito Angione, Cathryn Anne Scott, Giovanna De Maglio, Stefano Pizzolitto, Carla Di Loreto, Fabio Puglisi, Gianpiero Fasola, Alessandro Marco Minisini
Age is an important prognostic factor in melanoma; notably, elderly patients tend to present with advanced stage skin melanoma (SM) and worse outcome. Moreover, SM is an immunogenic cancer, and its interaction with the aging immune system could have an effect on biologic behaviour of this disease. Tumour-infiltrating lymphocytes (TILs) could represent the host response in SM; it has been shown that higher grade of TILs is associated with better survival. Moreover, programmed death ligand 1 (PD-L1) and cyclooxygenase-2 (COX-2) are potential markers of host immune response and inflammation...
May 22, 2018: Melanoma Research
Julia Brütting, Maike Bergmann, Marlene Garzarolli, Ricarda Rauschenberg, Christiane Weber, Carola Berking, Wolfgang Tilgen, Dirk Schadendorf, Friedegund Meier
There is a scarcity of available data on unmet information needs (UINs) of melanoma patients (MPs) from Germany and of MPs with clinical stage IV. In a multicenter cross-sectional survey, we explored the UINs of 529 MPs by applying a standardized questionnaire. Subgroup differences in scope and contents of UINs were determined by univariate analyses. Predictors of the presence of UINs were identified by binary logistic regression. Overall, 55% of MPs reported UINs. Most MPs felt poorly or not informed about psychosocial support (24-31%)...
May 21, 2018: Melanoma Research
Paweł Teterycz, Paulina Jagodzińska-Mucha, Bożena Cybulska-Stopa, Anna Mariuk-Jarema, Katarzyna Kozak, Hanna Koseła-Paterczyk, Anna M Czarnecka, Marcin Rajczykowski, Robert Dziura, Łukasz Galus, Jacek Mackiewicz, Tomasz Świtaj, Anna Klimczak, Slawomir Falkowski, Rafał Suwiński, Marek Ziobro, Iwona Ługowska, Piotr Rutkowski
Neutrophil-to-lymphocyte ratio (NLR) has been shown to be prognostic in several solid malignancies. There are limited data regarding its value during novel therapies in patients with melanoma. The aim of the study was to assess the practical utility of this ratio in patients with BRAF-mutant melanoma treated with a combination of BRAF and MEK inhibitors (BRAFi/MEKi). We included 215 patients with inoperable or metastatic melanoma who underwent BRAFi/MEKi treatment between October 2015 and June 2017. Baseline NLR and other complete blood count-derived inflammatory markers were tested for association with overall survival and progression-free survival in univariate and multivariate models...
May 18, 2018: Melanoma Research
Alexander Thiem, Patrick Schummer, Simon Ueberschaar, Andreas Kerstan, Hermann Kneitz, David Schrama, Silke Appenzeller, Svenja Meierjohann, Bastian Schilling, Matthias Goebeler, Anja Gesierich
Anti-PD-1 targeted immunotherapies have revolutionized the treatment of advanced melanoma and other tumor entities, and long disease-free intervals have been reported in responding patients. However, a considerable number of patients still progress rapidly after the start of anti-PD-1 antibodies. Here, we document two patients, 78 and 85-year old, who suffered from advanced BRAF-V600 wild-type melanoma and received pembrolizumab 2 mg/kg every 3 weeks as the first systemic treatment. After only one, respectively, two infusions of pembrolizumab, both patients developed melanuria and diffuse melanosis cutis (DMC) on sun-exposed areas of their skin...
May 17, 2018: Melanoma Research
Henri Montaudié, Alexandra Picard, Patricia Panaia-Ferrari, Fériel Boukari, Thierry Passeron, Jean-Louis Sadoul, Françoise Brucker-Davis
No abstract text is available yet for this article.
August 2018: Melanoma Research
Anamaria S Facina, Gil Facina, Ismael D C Guerreiro da Silva, Silvana A A Corrêa, Sandra M Alexandre, Ângela F Logullo, Jorge K Hosomi, Mary U Nakamura
Pregnancy-associated melanoma is defined as melanoma diagnosed during pregnancy or within 1 year of delivery. The association of pregnancy with melanoma is well known, but its underlying molecular mechanisms of association are poorly understood. The aim was to assess the expression of apoptosis-related genes in melanoma tumors during pregnancy in an attempt to elucidate the molecular mechanisms underlying apoptosis-driven activation of melanoma cells in this period. Mice were allocated across two experimental groups (nonpregnant and pregnant) and implanted with the melanoma cell line BF16-F10...
August 2018: Melanoma Research
Xue Zhou, Yong Zeng, Huayong Jiang, Limei Xia, Chuan Liu
Epidemiological studies have assessed the association between excision repair cross-complementing group 2 (ERCC2) Lys751Gln and Asp312Asn polymorphisms and melanoma risk with conflicting results. Relevant articles were searched from PubMed, Embase, and Web of Science with a time limit of 3 September 2016. Pooled odds ratio (OR) with 95% confidence interval (CI) was used to assess the strength of the association. We performed this meta-analysis with 12 studies including 6157 cases and 8873 controls for Lys751Gln and nine studies including 5037 cases and 7542 controls for Asp312Asn polymorphism...
August 2018: Melanoma Research
Dimosthenis Tsoutsos, Stefanos Papadopoulos, George Kehagias, Aristea Mara, Eugenia Kyriopoulou, Athanasios Karonidis, Konstantinos Spiliopoulos, Efstathios Mpalitsaris, George Karapiperis, Peter Panayotou, Eugenia Papaliodi, Theodosia Choreftaki, George Papaxoinis, Olga Benopoulou, John Ioannovich, Helen Gogas
The aim of this study was to present the epidemiological, clinicopathological, and treatment characteristics of patients diagnosed and treated in a tertiary referral center and to analyze independent factors associated with these characteristics. In this cohort study, epidemiological, clinicopathological, and treatment characteristics of 1461 consecutive melanoma patients diagnosed and treated in a tertiary referral center in 1987-2015 were prospectively collected in a registry. All patients underwent resection of their melanoma lesion...
August 2018: Melanoma Research
Muhammad Z Afzal, Keisuke Shirai
Denosumab is a monoclonal antibody against RANK ligand with a role in the prevention of skeletal-related events and is also known to possess antitumor properties. In this retrospective review, we aim to evaluate the synergist effect of a combination therapy with immune checkpoint inhibitors and denosumab in malignant melanoma patients. Patients of 18 years of age or older with a diagnosis of malignant melanoma who have received immune checkpoint inhibitors and denosumab between June 2015 and May 2017 were divided into two cohorts: cohort A (immune checkpoint inhibitors only) and cohort B (immune checkpoint inhibitors and denosumab)...
August 2018: Melanoma Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"